Showing 1 - 3 of 3
Potential Impact of Takeda’s Dengue Vaccine Candidate Reinforced by Long-Term Safety and Efficacy Results
Published on 24/05/2021
» •Takeda’s dengue vaccine candidate (TAK-003) prevented 83.6% of hospitalizations and 62.0% of dengue illness overall, with no identified important safety risks through three years following vaccination in ongoing pivotal Phase 3 TIDES trial • Regulatory filings for TAK-003 progressing in European Union and in many dengue-endemic countries; filing in United States planned for later this year • Dengue is the fastest-spreading mosquito-borne viral disease with an estimated 390 million cases and 500,000 hospitalizations per year globally, with limited options for prevention
SET gains as global bourses fret about Greece
Business, Published on 29/06/2015
» Recap: The Greek debt crisis cast a cloud over global stock markets last week but Thailand staged a modest rally. Chinese stocks plummeted 8% on Friday as investors rushed to cash out amid signs that an eight-month bull run was ending.
Set stalls despite high turnover, global optimism
Business, Published on 10/11/2014
» Recap: US and European markets surged last week. The Dow Jones Industrial Average hit a new high, buoyed by signals from the European Central Bank (ECB) signal that it stands ready to introduce more economic stimulus measures if necessary.